



## MINUTES

### CIBMTR WORKING COMMITTEE FOR LYMPHOMA

Honolulu, HI

Friday, February 14, 2025, 1:00 – 3:00 PM HST

Co-Chair:	Cameron Turtle, MBBS, PhD; University of Sydney, Sydney, NSW, Australia; E-mail: cameron.turtle@sydney.edu.au
Co-Chair:	Alex Herrera, MD; City of Hope National Medical Center, Duarte, CA; Telephone: 626-256-4673; E-mail: aherrera@coh.org
Co-Chair:	Mazyar Shadman, MD, MPH; Fred Hutchinson Cancer Research Center, Seattle, WA; Telephone: 206-667-5467; E-mail: mshadman@fredhutch.org
Scientific Director:	Mehdi Hamadani, MD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-805-0643; E-mail: mhamadani@mcw.edu
Statistical Director:	Kwang Woo Ahn, PhD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-456-7387; E-mail: kwoohahn@mcw.edu
Statistician:	Jinalben Patel, MPH; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; E-mail: jipatel@mcw.edu

---

## 1. Introduction

- a. Minutes from February 2024 (Attachment 1)

## 2. Accrual summary (Attachment 2)

## 3. Presentations, Publications or Submitted papers

- a. **LY22-01c** Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: A Center for International Blood and Marrow Transplant Research analysis. *Leukemia*. 2024 Jul 1; 38(7):1564-1569. doi:10.1038/s41375-024-02242-6. Epub 2024 May 15. PMC11271761.
- b. **LY22-02a** Epperla N, Hashmi H, Ahn KW, Chen AI, Wirk B, Kanakry JA, Lekakis L, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. *British Journal of Haematology*. 2024 Sep 1; 205(3):1202-1207. doi:10.1111/bjh.19569. Epub 2024 May 26. PMC11499028.
- c. **LY22-01a** Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjane A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Autologous transplant vs. CAR-T therapy in patients

with DLBCL treated while in complete remission. *Blood Cancer Journal*. 14(1):108. doi:10.1038/s41408-024-01084-w. Epub 2024 Jul 8. PMC11231252.

- d. **LY22-01b** Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M. CD19-directed CART therapy for T cell/histiocyte rich large B-cell lymphoma. *Blood Advances*. 2024 Oct 22; 8(20):5290-5296. doi:10.1182/bloodadvances.2024013863. Epub 2024 Jul 14. PMC11497379.
- e. **LY22-01a** Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Ramakrishnan Geethakumari P, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ. Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. *Haematologica*. doi:10.3324/haematol.2024.285613. Epub 2024 Sep 5.
- f. **LY22-02b** Outcomes of autologous HCT and CD19 CAR-T in MYC+ large B-cell lymphoma patients. (M Hamadani/ F Furqan). *Submitted*.
- g. **LY20-02** Outcomes of allogeneic transplants in patients with hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis. (M-A Perales/ A Sureda/ F Awan/ S Montoto). *Submitted*.

#### 4. Studies in progress (Attachment 3)

- a. **LY22-02c** Efficacy and safety of CD19 directed CAR T-cell therapy for transferred follicular lymphoma (S Kambhampati/ K Nadiminti/ A Herrera). **Manuscript Preparation**.
- b. **LY22-02d** Efficacy and safety of CD19 directed CAR T-cell therapy for Richter's transformation (M Shadman/ M Hamadani). **Manuscript Preparation**.
- c. **LY22-02e** Efficacy and safety of CD19 directed CAR T-cell therapy for primary mediastinal B-cell lymphoma (J Gauthier/ A Herrera). **Manuscript Preparation**.
- d. **LY22-02f** Efficacy and safety of CD19 directed CAR T-cell therapy for high grade B-cell lymphoma. (S Ahmed/ S Mercadal/ H Hashmi/ C Lee/ N Epperla). **Manuscript Preparation**.
- e. **LY23-01** Efficacy of hematopoietic stem cell transplantation in patients with plasmablastic lymphoma (S Ahmed/ T Al-Juhaishi). **Protocol Development**.
- f. **LY24-01** Hematopoietic cell transplantation for rare mature T-cell lymphomas (M Hamadani/ A Herrera). **Protocol Development**.

#### 5. Future/proposed studies

- a. **PROP 2410-44; 2410-168** Axi-cel vs. Liso-cel in Second line in DLBCL (A Mian/ B T. Hill/ D Reef/ N Grover) (Attachment 4)

*Dr. Reef presented.*

- **Hypothesis:** Axicel and Lysocel have different efficacy and toxicity profiles in second-line treatment for relapsed/refractory DLBCL.
- **Objectives:** Estimate progression-free survival, overall response rate, overall survival, complete response rates, and toxicity measures.

- b. **PROP 2410-66** A Matching Adjusted Indirect Comparison (MAIC) Analysis Comparing the Clinical Outcomes of Patients with Follicular Lymphoma Treated with Anti-CD19 Chimeric Antigen Receptor T Cell Therapy (CART) and Bispecific T Cell Engager (M Di/ M Shadman) (Attachment 5)

*Dr. Dai presented.*

- **Hypothesis:** CAR T cells have better efficacy compared to bispecific T cell engagers in relapsed/refractory follicular lymphoma.
- **Objectives:** Compare progression-free survival, overall survival, response rates, and safety outcomes between CAR T cells and bispecific antibodies.

- c. **PROP 2410-67** Real-world Outcomes Following Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Older Patients with Large B Cell Lymphoma (M Di/ M Shadman) (Attachment 6)

*Dr. Dai presented.*

- **Hypothesis:** Lysocel has similar efficacy but better safety compared to Axicel in older patients with relapsed/refractory large B-cell lymphoma.
- **Objectives:** Compare progression-free survival, overall survival, and safety endpoints between Axicel and Lysocel.

- d. **PROP 2410-72; 2410-239** Brux-cel in older MCL patients (S Gupta/ V Bachanova/ P Jain/ A Lionel) (Attachment 7)

*Dr. Gupta presented.*

- **Hypothesis:** Older patients with relapsed/refractory mantle cell lymphoma treated with Brexucel demonstrate comparable response rates and survival outcomes.
- **Objectives:** Compare objective and complete response rates, progression-free survival, overall survival, and cumulative incidence of grade 3 or higher CRS and ICANS.

- e. **PROP 2410-100** Incidence and Risk factors for Non-relapse Mortality after anti-CD19 CAR T-cell therapy for Lymphoma (D Modi) (Attachment 8)

*Dr. Modi presented.*

- **Hypothesis:** Non-relapse mortality is a significant complication of CAR T-cell therapy for B-cell non-Hodgkin lymphoma.
- **Objectives:** Estimate cumulative incidence of non-relapse mortality, identify timing and risk factors, and evaluate association with different CAR T-cell products.

- f. **PROP 2410-120; 2410-194** AutoHCT in Secondary CNS lymphoma (B Gattas/ U Gergis/ A Kidwell/ N N. Shah) (Attachment 9)

*Dr. Kidwell presented.*

- **Hypothesis:** Consolidated autologous stem cell transplant improves outcomes for patients with secondary CNS lymphoma.
- **Objectives:** Compare progression-free survival, overall survival, and subgroup analyses based on frontline therapy and conditioning regimen.

**Proposed studies; not accepted for consideration at this time.**

- g. **PROP 2401-01** Impact of mogamulizumab on GVHD in patients receiving post-transplantation cyclophosphamide based GVHD prophylaxis (C Sterling). **Dropped due to small sample size.**
- h. **PROP 2407-01** Outcome of CART therapy post allogeneic HSCT (J L Wagner). **Dropped due to low scientific impact.**

- i. **PROP 2408-07** Real world outcomes of second chimeric antigen receptor T cell (CAR T-cell) therapy for lymphoma (J Joseph). ***Dropped due to low scientific impact.***
- j. **PROP 2409-13** Autologous stem cell transplant vs chimeric antigen receptor T-cell therapy in older patients with chemosensitive late relapsed diffuse large B-cell lymphoma (A Tun/ P Johnston). ***Dropped due to low scientific impact.***
- k. **PROP 2409-14** Autologous stem cell transplant vs chimeric antigen receptor T-cell therapy in follicular lymphoma with early treatment failure (A Tun/ C Sauter). ***Dropped due to low scientific impact.***
- l. **PROP 2409-32** The impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-CAR-T (R Shouval). ***Dropped due to supplemental data needed.***
- m. **PROP 2410-12** Outcomes of HIV+ Lymphoma treated with Chimeric Antigen Receptor T-Cell Therapy (M Iqbal/ H Murthy). ***Dropped due to overlap with current study/publication.***
- n. **PROP 2410-13** Outcomes and Utilization Trends of Autologous Hematopoietic Cell Transplantation for Classical Hodgkin Lymphoma (M Iqbal/ M Kharfan-Dabaja). ***Dropped due to low scientific impact.***
- o. **PROP 2410-15** Evaluating Outcomes of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma in the Contemporary Era (M Iqbal/ M Kharfan-Dabaja). ***Dropped due to low scientific impact.***
- p. **PROP 2410-19** Use of PD1 Inhibitors as Salvage Therapy Prior to Autologous Stem Cell Transplantation (ASCT) in Hodgkin Lymphoma (Y Berry/ S Farhan). ***Dropped due to low scientific impact.***
- q. **PROP 2410-42** Outcomes of CAR-T in DLBCL Based on Remission Status (A Sindel). ***Dropped due to low scientific impact.***
- r. **PROP 2410-64** Real world comparison of efficacy of bispecific antibodies (BsAbs) and chimeric antigen receptor T-cell therapies (CART) in large B-cell lymphoma (LBCL) (T Zhuang/ P Strati). ***Dropped due to small sample size.***
- s. **PROP 2410-65** Impact of checkpoint inhibitors on outcomes after autologous stem cell transplant for relapsed Hodgkin's lymphoma (P Pophali/ D Trotier). ***Dropped due to low scientific impact.***
- t. **PROP 2410-68** CD19 Directed CAR-T therapy Outcomes in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) as Determined by Tumor Size (& burden) and Lactate Dehydrogenase Enzyme (LDH) (A Desai/ R Maziarz). ***Dropped due to overlap with current study/publication.***
- u. **PROP 2410-83** The impact of novel therapies and modern antiretroviral therapy on outcomes after autologous stem cell transplant in patients with relapsed and refractory HIV-associated lymphoma (K Lurain/ A Herrera). ***Dropped due to overlap with current study/publication.***
- v. **PROP 2410-88** Predictive Modeling for CAR-T Therapies in Relapsed/Refractory Follicular Lymphoma Using Machine Learning (N Ahmed/ S Irfan). ***Dropped due to low scientific impact.***
- w. **PROP 2410-98** Outcomes of Hematopoietic Cell Transplantation and CAR T-Cell Therapy for Denovo CD5+ Diffuse Large B-Cell Lymphoma (B Wirk). ***Dropped due to small sample size.***
- x. **PROP 2410-105** Outcomes of CD3/CD20 bispecific antibodies and other targeted therapies post CD19 CAR T therapy in relapsed refractory diffuse large B-cell lymphoma (S Thiruvengadam/ A Herrera). ***Dropped due to small sample size.***
- y. **PROP 2410-108** Outcomes of R/R large B-cell lymphoma patients treated with CD19 CAR T cell therapy previously exposed to bispecific antibody with propensity score matching comparison to those naïve to bispecific antibody (S Thiruvengadam/ A Herrera). ***Dropped due to small sample size.***

- z. **PROP 2410-110** Outcomes of R/R FL patients treated with CD19 CAR T cell therapy previously exposed to bispecific antibody with propensity score matching comparison to those naïve to bispecific antibody (S Thiruvengadam/ A Herrera). ***Dropped due to small sample size.***
- aa. **PROP 2410-112** Comparative efficacy of CD19+CAR-T vs autoHCT in 2L DLBCL based on the putative cell of origin (ABC vs GCB) (M Abid/ S Ahmed). ***Dropped due to low scientific impact.***
- bb. **PROP 2410-113** Efficacy of a second CAR-T infusion in patients with relapsed/refractory B-cell malignancies (M Abid/ S Ahmed). ***Dropped due to low scientific impact.***
- cc. **PROP 2410-114** Outcomes of Burkitt lymphoma Patients Undergoing Autologous and Allogeneic hematopoietic cell transplantation: A contemporary analysis (I Muhsen/ M Aljurf). ***Dropped due to low scientific impact.***
- dd. **PROP 2410-115** Real-World Outcomes of CD19+CAR-T and Comparison of Axi-cel vs Tisa-cel for Relapsed/refractory Follicular Lymphoma (M Abid/ S Ahmed). ***Dropped due to low scientific impact.***
- ee. **PROP 2410-116** Efficacy of Autologous Stem Cell Transplant in DLBCL Patients Who Relapse After CAR T-Cell Therapy (M Abid/ S Ahmed). ***Dropped due to low scientific impact.***
- ff. **PROP 2410-117** Analysis of Commercial CD19+CAR-T Therapy for Patients with relapsed/refractory Aggressive Large B Cell Lymphoma in the real-world third line Setting (M Abid/ S Ahmed). ***Dropped due to low scientific impact.***
- gg. **PROP 2410-127** Real-world non-relapse mortality and early mortality after brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy for mantle cell lymphoma (P Jain/ A Lionel). ***Dropped due to low scientific impact.***
- hh. **PROP 2410-132** Comparative outcome analysis of patients with primary refractory or early relapsed aggressive B-cell lymphoma treated with axicabtagene ciloleucel versus lisocabtagene maraleucel (X Bi/ U Gergis). ***Dropped due to low scientific impact.***
- ii. **PROP 2410-150** Outcomes of autologous stem cell transplantation in DLBCL relapsed/refractory to CD19 CAR T (S Thiruvengadam/ E Bezerra). ***Dropped due to low scientific impact.***
- jj. **PROP 2410-162** A comparison of the safety and efficacy of anti-CD19 CAR T-cell therapy versus autologous stem cell transplantation (ASCT) in follicular lymphoma experiencing early therapy failure (POD12 and POD24) (H Wolfe/ P Ramakrishnan). ***Dropped due to low scientific impact.***
- kk. **PROP 2410-164** Outcomes of subsequent transplant or cellular therapy for relapse after CD19 autologous CAR T-cell therapy in large B-cell lymphoma (H Cherniawsky/ R J Stubbins). ***Dropped due to low scientific impact.***
- ll. **PROP 2410-166** Real-world Outcomes Following Lisocabtagene Maraleucel in Patients with Mantle Cell Lymphoma (J Huang/ M Shadman). ***Dropped due to small sample size.***
- mm. **PROP 2410-170** Optimizing CAR-T in Follicular Lymphoma: Identifying the Best Line of Therapy to Maximize Survival (D Reef/ N Grover). ***Dropped due to low scientific impact.***
- nn. **PROP 2410-171** Effect of Prior CD19-Targeted Therapies and CD3xCD20 Bispecific Antibodies on Subsequent Anti-CD19 CAR T-Cell Therapy Outcomes in Diffuse Large B-cell Lymphoma (E Yilmaz/ F Awan). ***Dropped due to small sample size.***
- oo. **PROP 2410-185** Efficacy and Toxicity of CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma Previously Treated with Bispecific Antibodies (J Huang/ M Shadman). ***Dropped due to small sample size.***

- pp. **PROP 2410-189** Efficacy of a second CAR T-cell therapy in patients with Relapse/Refractory B-cell non-Hodgkin lymphoma (A Kidwell/ N Shah). ***Dropped due to low scientific impact.***
- qq. **PROP 2410-197** Efficacy and safety of CD19 CAR T cell therapy in EBV-positive diffuse large B-cell lymphoma (M Alhomoud/ M Scordo). ***Dropped due to small sample size.***
- rr. **PROP 2410-198** Evaluating outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T Cell Lymphoma (M Iqbal/ H Murthy). ***Dropped due to overlap with current study/publication.***
- ss. **PROP 2410-215** Real-world efficacy of anti-CD19-chimeric antigen receptor T cell therapy in the second-line setting for late-relapsed large B cell lymphoma (S Ahmed/ K Chohan). ***Dropped due to low scientific impact.***
- tt. **PROP 2410-216** Post-autologous stem cell transplant outcomes of primary mediastinal B-cell lymphoma patients with prior exposure to checkpoint inhibitors (S Larson/ J Timmerman). ***Dropped due to overlap with current study/publication.***
- uu. **PROP 2410-219** Outcomes of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory large B cell lymphoma with testicular involvement – an efficacy analysis of CAR-T for a rare sanctuary site (G Hildebrandt/ M Yasir). ***Dropped due to small sample size.***
- vv. **PROP 2410-226** A Matched Adjusted Indirect Comparison of Safety and Efficacy of CD20-directed BiTE therapy versus CD19-directed CAR-T therapy in LBCL (K Chetlapalli/ L Gowda). ***Dropped due to low scientific impact.***
- ww. **PROP 2410-236** Real-world analysis of brexucabtagene autoleucel as compared to allogeneic transplant for patients with high-risk mantle cell lymphoma (S Ahmed/ K Chohan). ***Dropped due to low scientific impact.***
- xx. **PROP 2410-238** Outcomes of Subsequent CD19-directed CAR-T infusion after relapse from prior CAR-T cell therapy for B cell malignancies (S Mirza/ L Gowda). ***Dropped due to low scientific impact.***
- yy. **PROP 2410-243** Efficacy and toxicity of allogeneic transplantation post-chimeric antigen receptor T cell therapy failure in large B cell lymphoma Cri (S Ahmed/ K Chohan). ***Dropped due to low scientific impact.***
- zz. **PROP 2410-244** Impact of BTK Inhibitor Maintenance Therapy on Outcomes Following CAR T-Cell Therapy in Mantle Cell Lymphoma (O Jarallah/ S Mirza). ***Dropped due to supplemental data needed.***
- aaa. **PROP 2410-252** Outcomes and toxicity of autologous stem cell transplant for patients with Primary CNS Lymphoma associated with HIV (L Schachter/ J Cleveland). ***Dropped due to small sample size.***
- bbb. **PROP 2410-263** Survival Outcomes of Allogeneic Transplants (allo-SCT) in comparison to Chimeric Antigen Receptor (CAR T) therapy for Relapsed Refractory Mantle Cell lymphoma (MCL) (S Naik/ C Annageldiyev). ***Dropped due to low scientific impact.***

## 6. Other business